The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.

A recent report found no substantial (statistically significant) differences in either 30-day or 1-year mortality in users of various sulfonylureas after myocardial infarction (although use of gliclazide monotherapy showed a trend toward lower mortality [hazard ratio 0.70 {95% CI 0.48–1.0}]), suggesting that mortality is not substantially influenced by the choice of sulfonylurea ( 17 ).

also in 53,322 other papers

There were significantly fewer patients in the CAD subanalysis, and the results showed a strong trend toward a reduced risk with glimepiride.

also in 5,725 other papers